SI3037089T1 - Etilester eikozapentaenojske kisline za zdravljenje hipertrigliceridemije - Google Patents
Etilester eikozapentaenojske kisline za zdravljenje hipertrigliceridemijeInfo
- Publication number
- SI3037089T1 SI3037089T1 SI201031980T SI201031980T SI3037089T1 SI 3037089 T1 SI3037089 T1 SI 3037089T1 SI 201031980 T SI201031980 T SI 201031980T SI 201031980 T SI201031980 T SI 201031980T SI 3037089 T1 SI3037089 T1 SI 3037089T1
- Authority
- SI
- Slovenia
- Prior art keywords
- ethyl ester
- acid ethyl
- eicosapentaenoic acid
- treating hypertriglyceridemia
- hypertriglyceridemia
- Prior art date
Links
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 title 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 title 1
- 208000006575 hypertriglyceridemia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15129109P | 2009-02-10 | 2009-02-10 | |
US17375509P | 2009-04-29 | 2009-04-29 | |
EP16152447.5A EP3037089B1 (en) | 2009-02-10 | 2010-02-09 | Eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3037089T1 true SI3037089T1 (sl) | 2020-03-31 |
Family
ID=42102041
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201031979T SI2596786T1 (sl) | 2009-02-10 | 2010-02-09 | Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije |
SI201031980T SI3037089T1 (sl) | 2009-02-10 | 2010-02-09 | Etilester eikozapentaenojske kisline za zdravljenje hipertrigliceridemije |
SI201030313T SI2395991T1 (sl) | 2009-02-10 | 2010-02-09 | Uporaba etil estra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201031979T SI2596786T1 (sl) | 2009-02-10 | 2010-02-09 | Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201030313T SI2395991T1 (sl) | 2009-02-10 | 2010-02-09 | Uporaba etil estra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije |
Country Status (24)
Country | Link |
---|---|
US (29) | US8293727B2 (sl) |
EP (5) | EP3037089B1 (sl) |
KR (2) | KR101383006B1 (sl) |
AU (1) | AU2010213899B2 (sl) |
BR (1) | BRPI1007518A2 (sl) |
CA (3) | CA3089847C (sl) |
CY (2) | CY1122628T1 (sl) |
DK (3) | DK2395991T3 (sl) |
ES (3) | ES2768091T3 (sl) |
HK (2) | HK1165698A1 (sl) |
HR (3) | HRP20130811T1 (sl) |
HU (1) | HUE048299T2 (sl) |
LT (2) | LT3037089T (sl) |
MX (1) | MX2011008448A (sl) |
NZ (1) | NZ594395A (sl) |
PH (1) | PH12015500407B1 (sl) |
PL (3) | PL3037089T3 (sl) |
PT (3) | PT3037089T (sl) |
RU (2) | RU2505292C2 (sl) |
SG (3) | SG173612A1 (sl) |
SI (3) | SI2596786T1 (sl) |
SM (1) | SMT201300095B (sl) |
WO (1) | WO2010093634A1 (sl) |
ZA (1) | ZA201105612B (sl) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
PL2376077T3 (pl) | 2009-01-12 | 2017-10-31 | Biokier Inc | Kompozycja i sposób leczenia cukrzycy |
LT3037089T (lt) | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
EP2480246A4 (en) | 2009-09-23 | 2013-02-27 | Biokier Inc | COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
WO2011087981A2 (en) | 2010-01-15 | 2011-07-21 | E. I. Du Pont De Nemours And Company | Clinical benefits of eicosapentaenoic acid in humans |
RU2728825C2 (ru) * | 2010-03-04 | 2020-07-31 | Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания |
NZ727980A (en) * | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US11291643B2 (en) * | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP3348262A1 (en) | 2012-01-06 | 2018-07-18 | Omthera Pharmaceuticals Inc. | Methods for making dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
US20150347716A1 (en) * | 2012-02-14 | 2015-12-03 | Photonz Corporation Ltd. | Method for Supervising Consumption of a Medical Food for Prevention and/or Management of a Disease or Condition |
JP6173437B2 (ja) | 2012-05-07 | 2017-08-02 | オムセラ・ファーマシューティカルズ・インコーポレイテッド | スタチン及びω−3脂肪酸の組成物 |
US9700538B2 (en) | 2012-05-15 | 2017-07-11 | Mochida Pharmaceutical Co., Ltd. | Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity C-reactive protein |
WO2013192109A1 (en) | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
RS61557B1 (sr) * | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
US20140005265A1 (en) * | 2012-06-29 | 2014-01-02 | Amarin Pharmaceuticals Ireland Limited | Methods for treating hypertriglyceridemia |
US20150157593A1 (en) * | 2012-06-29 | 2015-06-11 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing ldl-p |
US20140004183A1 (en) * | 2012-06-29 | 2014-01-02 | Amarin Pharmaceuticals Ireland Limited | Methods for treating cardiovascular disease in statin-tolerant subjects |
KR102103426B1 (ko) * | 2012-09-28 | 2020-04-22 | 모치다 세이야쿠 가부시키가이샤 | 당뇨병 신규 발병 저감용 조성물 |
WO2014074552A2 (en) * | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US20140213648A1 (en) * | 2012-12-31 | 2014-07-31 | Amarin Pharmaceuticals Ireland Limited | Methods of increasing epa blood levels |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140221452A1 (en) * | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US20140221358A1 (en) * | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
WO2014158256A1 (en) * | 2013-03-13 | 2014-10-02 | Matinas Biopharma Inc. | Omega-3 pentaenoic acid compositions and methods of use |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
KR102039522B1 (ko) * | 2013-06-03 | 2019-11-26 | 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. | 근거리 무선 통신(nfc)을 이용한 nfc 태그의 기록방법 및 장치 |
US20140357717A1 (en) * | 2013-06-04 | 2014-12-04 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
JP6804823B2 (ja) * | 2013-10-14 | 2020-12-23 | アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティーArizona Board of Regents on behalf of Arizona State University | 白金錯体およびデバイス |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10547995B2 (en) * | 2015-04-30 | 2020-01-28 | Lg Electronics Inc. | Method and device for transmitting/receiving data using Bluetooth mesh network |
US10183044B2 (en) | 2015-05-15 | 2019-01-22 | P Tech, Llc | Systems and methods for thrombosis prevention |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
CA3080818A1 (en) | 2017-10-30 | 2019-05-09 | Montreal Heart Institute | Methods of treating elevated plasma cholesterol |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377526A (en) | 1981-05-15 | 1983-03-22 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid and its esters |
US4526902A (en) | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
CA1239587A (en) | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
JPS6135356A (ja) * | 1984-07-27 | 1986-02-19 | Nippon Oil & Fats Co Ltd | 血液脂質脂肪酸の分析方法 |
US4920098A (en) | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
US5252333A (en) | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
US5198468A (en) | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
US4843095A (en) | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
CA1338683C (en) | 1988-09-13 | 1996-10-29 | Efamol Holdings Plc | Fatty acid therapy and compositions |
GB2223943A (en) | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
US4935243A (en) | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
JP2839276B2 (ja) | 1989-01-23 | 1998-12-16 | 日本分光工業株式会社 | 超臨界流体抽出・分離方法及び装置 |
GB8906369D0 (en) | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
US5457130A (en) | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
CA2043615C (en) | 1990-06-04 | 2001-08-14 | Kazuhiko Hata | Method of producing eicosapentaenoic acid or the ester derivative thereof |
GB9012651D0 (en) | 1990-06-06 | 1990-07-25 | Efamol Holdings | Essential fatty acid treatment |
JP3103588B2 (ja) | 1990-11-16 | 2000-10-30 | 持田製薬株式会社 | リポプロテイン(a)低下剤 |
SE9101642D0 (sv) | 1991-05-30 | 1991-05-30 | Kabi Pharmacia Ab | Phospholipids |
US5215630A (en) | 1991-06-04 | 1993-06-01 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation |
AU2384292A (en) * | 1991-07-30 | 1993-03-02 | North Carolina State University | Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy |
DE4133694C2 (de) | 1991-10-11 | 1993-10-07 | Fresenius Ag | Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen |
JP3400466B2 (ja) | 1991-10-28 | 2003-04-28 | 日本水産株式会社 | 高純度エイコサペンタエン酸またはそのエステルの製造方法 |
JPH0649479A (ja) | 1992-07-28 | 1994-02-22 | Maruha Corp | ω−3不飽和脂肪酸系化合物の安定化法 |
US5888541A (en) | 1992-08-21 | 1999-03-30 | Scotia Holdings Plc | Fatty acid treatment |
GB9217780D0 (en) | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
GB9300125D0 (en) | 1993-01-06 | 1993-03-03 | Scotia Holdings Plc | Compositions containing esters of unsaturated fatty acids |
AU7053494A (en) | 1993-06-04 | 1995-01-03 | Martek Biosciences Corporation | Method of treating coronary vascular disease using docosahexaenoic acid |
GB9403857D0 (en) | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
US5760081A (en) | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
AU711482B2 (en) | 1994-06-28 | 1999-10-14 | Scotia Holdings Plc | Compositions for treatment of diabetic complications |
IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
GB9519661D0 (en) | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
AU2738497A (en) | 1996-04-24 | 1997-11-12 | Brigham And Women's Hospital | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder |
TW425285B (en) | 1996-06-10 | 2001-03-11 | Viva America Marketing Inc | Fish oil and garlic nutritive supplement |
US5861399A (en) | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
US20020055539A1 (en) | 1996-10-02 | 2002-05-09 | Bockow Barry I. | Compositions and methods for treating cardiovascular conditions |
KR20060061409A (ko) | 1996-10-11 | 2006-06-07 | 스카리스타 리미티드 | 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일 |
US20010006644A1 (en) | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
KR100569319B1 (ko) | 1997-10-30 | 2006-04-07 | 모리시타 진탄 가부시키가이샤 | 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법 |
DE69842121D1 (de) | 1997-12-10 | 2011-03-17 | Cyclosporine Therapeutics Ltd | Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen |
US20020055529A1 (en) | 1998-12-02 | 2002-05-09 | Bisgaier Charles Larry | Method for treating alzheimer's disease |
GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
US6193999B1 (en) | 1999-03-01 | 2001-02-27 | Banner Pharmacaps, Inc. | Gum acacia substituted soft gelatin capsules |
ATE394941T1 (de) | 1999-07-28 | 2008-05-15 | Swiss Caps Rechte & Lizenzen | Präparat zur verwendung als medikament und/oder nahrungsmittelergänzung |
WO2001015552A1 (en) | 1999-08-30 | 2001-03-08 | Ocean Nutrition Canada Ltd. | A nutritional supplement for lowering serum triglyceride and cholesterol levels |
DK1157692T3 (da) | 2000-05-22 | 2006-02-06 | Pro Aparts Investimentos E Con | Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf |
GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
DZ3409A1 (fr) | 2000-08-15 | 2002-02-21 | Pfizer Prod Inc | Association therapeuthique |
ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
GB0111282D0 (en) | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
PT1390025E (pt) | 2001-05-30 | 2005-08-31 | Laxdale Ltd | Utilizacao de coenzima q (ubiquinona) e acido eicosapentaenoico (epa) para o tratamento de linfoma nao de hodgkin e de distubios psiquiatricos ou neurologicos |
ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
ITMI20020269A1 (it) | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
HUP0200686A2 (hu) | 2002-02-22 | 2003-09-29 | EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. | Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül |
US20030166614A1 (en) | 2002-03-01 | 2003-09-04 | Harrison Stanley F. | Method for reducing cholesterol and triglycerides |
US7157235B2 (en) * | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US7314643B2 (en) | 2002-08-20 | 2008-01-01 | Nikken Chemicals Co., Ltd. | Soft capsule preparation |
TW200418957A (en) | 2002-11-22 | 2004-10-01 | Nippon Suisan Kaiaha Ltd | Compositions for external use containing polyunsaturated fatty acids salts thereof or esters thereof and method of manufacturing the same |
GB0228079D0 (en) | 2002-12-02 | 2003-01-08 | Laxdale Ltd | Huntington's Disease |
CN1756545A (zh) | 2003-03-05 | 2006-04-05 | 索尔瓦药物有限公司 | ω-3-脂肪酸在治疗糖尿病患者中的应用 |
EP1605781A1 (en) | 2003-03-18 | 2005-12-21 | Novartis AG | Compositions comprising fatty acids and amino acids |
ITMI20032247A1 (it) | 2003-11-19 | 2005-05-20 | Tiberio Bruzzese | Interazione di derivati polari di composti insaturi con substrati inorganici |
GB2409644B (en) | 2003-12-31 | 2005-12-21 | Igennus Ltd | Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof |
US7022713B2 (en) | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
US20050272095A1 (en) * | 2004-05-19 | 2005-12-08 | Ppd Biomarker Discovery Sciences, Llc | Methods of identifying biomarkers |
JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
ITRM20040395A1 (it) | 2004-08-03 | 2004-11-03 | Sigma Tau Ind Farmaceuti | Composizione comprendente statine e acidi grassi omega 3. |
EP1786414A4 (en) | 2004-08-06 | 2008-04-09 | Transform Pharmaceuticals Inc | NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES |
KR20070053283A (ko) | 2004-09-13 | 2007-05-23 | 산텐 세이야꾸 가부시키가이샤 | 각결막장해 치료제 |
CN1759834B (zh) * | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
CA2581816A1 (en) | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Microcapsules comprising a methylxanthine and a corticosteroid |
JP5491697B2 (ja) | 2004-10-15 | 2014-05-14 | フォトンズ コーポレイション リミテッド | 高レベルオメガ−3および低レベル飽和脂肪酸を含む組成物 |
FR2878747B1 (fr) | 2004-12-03 | 2007-03-30 | Pierre Fabre Medicament Sa | Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih |
US20070191467A1 (en) | 2004-12-06 | 2007-08-16 | Reliant Pharmaceutical, Inc. | Statin and omega-3 fatty acids for lipid therapy |
CA2589654C (en) | 2004-12-06 | 2016-02-16 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids and dyslipidemic agent for lipid therapy |
US20060135610A1 (en) | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
GB2421909A (en) | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
US20060189682A1 (en) * | 2005-02-02 | 2006-08-24 | Payne Joseph E | Water soluble prodrugs of COX-2 inhibitors |
BRPI0607569A2 (pt) | 2005-03-08 | 2009-09-15 | Reliant Pharmaceuticals Inc | composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária |
CA2570763C (en) | 2005-07-08 | 2011-08-23 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing onset of cardiovascular events |
RU2290185C1 (ru) * | 2005-07-26 | 2006-12-27 | Дмитрий Николаевич Мясников | Композиция для нормализации липидного обмена и снижения массы тела и способ её получения |
AU2006275784A1 (en) | 2005-07-28 | 2007-02-08 | Reliant Pharmaceuticals, Inc. | Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof |
ITMI20051560A1 (it) | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6 |
WO2007051065A2 (en) | 2005-10-28 | 2007-05-03 | Numerate, Inc. | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
US20070104779A1 (en) | 2005-11-07 | 2007-05-10 | Rongen Roelof M | Treatment with omega-3 fatty acids and products thereof |
CA2628305C (en) | 2005-11-11 | 2014-05-06 | Mochida Pharmaceutical Co., Ltd. | Jelly composition |
CA2634139C (en) | 2005-12-20 | 2015-06-23 | Cenestra, Llc. | Omega 3 fatty acid formulations |
DK1800675T3 (da) | 2005-12-23 | 2011-09-05 | Nutricia Nv | Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens |
CN101365438A (zh) * | 2006-02-07 | 2009-02-11 | 持田制药株式会社 | 预防中风复发的组合物 |
WO2007128801A1 (en) | 2006-05-08 | 2007-11-15 | Novartis Ag | Combination of organic compounds |
ES2500063T3 (es) | 2006-05-31 | 2014-09-29 | Mochida Pharmaceutical Co., Ltd. | Composición para prevenir la aparición de acontecimiento cardiovascular en paciente con riesgo múltiple |
JP5658876B2 (ja) | 2006-07-05 | 2015-01-28 | フォトンズ コーポレーション リミテッド | 大規模従属栄養培養領域にて産生される超高純度epaと極性脂質 |
US20090304784A1 (en) | 2006-07-28 | 2009-12-10 | V. Mane Fils | Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component |
CN101553221A (zh) | 2006-10-10 | 2009-10-07 | 瑞莱恩特医药品有限公司 | 用于降低APO-B水平的抑制素和ω-3脂肪酸 |
US20080125490A1 (en) | 2006-11-03 | 2008-05-29 | My Svensson | Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids |
US20080306154A1 (en) | 2006-11-03 | 2008-12-11 | My Svensson | Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids |
WO2008088030A1 (ja) | 2007-01-17 | 2008-07-24 | Mochida Pharmaceutical Co., Ltd. | 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物 |
CA2677036A1 (en) | 2007-03-06 | 2008-09-12 | Bioriginal Food & Science Corp. | Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same |
CN102552213A (zh) | 2007-06-29 | 2012-07-11 | 武田药品工业株式会社 | 无缝胶囊 |
US20090182049A1 (en) | 2008-01-16 | 2009-07-16 | Joar Arild Opheim | Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans |
JPWO2009142242A1 (ja) | 2008-05-20 | 2011-09-29 | 持田製薬株式会社 | ハイリスク患者の心血管イベント予防用組成物 |
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
LT3037089T (lt) | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101579659B1 (ko) | 2010-11-04 | 2015-12-22 | 에프. 호프만-라 로슈 아게 | S-[2-([[1-(2-에틸부틸)-사이클로헥실]-카본일]아미노)페닐]2-메틸프로판티오에이트 및 크로스카멜로스 나트륨을 포함하는 조성물 |
US20140004183A1 (en) * | 2012-06-29 | 2014-01-02 | Amarin Pharmaceuticals Ireland Limited | Methods for treating cardiovascular disease in statin-tolerant subjects |
-
2010
- 2010-02-09 LT LTEP16152447.5T patent/LT3037089T/lt unknown
- 2010-02-09 PT PT161524475T patent/PT3037089T/pt unknown
- 2010-02-09 CA CA3089847A patent/CA3089847C/en active Active
- 2010-02-09 CA CA3008079A patent/CA3008079C/en active Active
- 2010-02-09 CA CA2751576A patent/CA2751576C/en active Active
- 2010-02-09 SI SI201031979T patent/SI2596786T1/sl unknown
- 2010-02-09 DK DK10704464.6T patent/DK2395991T3/da active
- 2010-02-09 WO PCT/US2010/023638 patent/WO2010093634A1/en active Application Filing
- 2010-02-09 PL PL16152447T patent/PL3037089T3/pl unknown
- 2010-02-09 ES ES13156122T patent/ES2768091T3/es active Active
- 2010-02-09 BR BRPI1007518-6A patent/BRPI1007518A2/pt not_active Application Discontinuation
- 2010-02-09 SI SI201031980T patent/SI3037089T1/sl unknown
- 2010-02-09 ES ES16152447T patent/ES2769926T3/es active Active
- 2010-02-09 KR KR1020117019164A patent/KR101383006B1/ko active IP Right Grant
- 2010-02-09 EP EP16152447.5A patent/EP3037089B1/en not_active Revoked
- 2010-02-09 NZ NZ594395A patent/NZ594395A/en unknown
- 2010-02-09 EP EP19193487.6A patent/EP3616694A1/en not_active Withdrawn
- 2010-02-09 SG SG2011057353A patent/SG173612A1/en unknown
- 2010-02-09 SI SI201030313T patent/SI2395991T1/sl unknown
- 2010-02-09 DK DK13156122.7T patent/DK2596786T3/da active
- 2010-02-09 DK DK16152447.5T patent/DK3037089T3/da active
- 2010-02-09 MX MX2011008448A patent/MX2011008448A/es active IP Right Grant
- 2010-02-09 LT LTEP13156122.7T patent/LT2596786T/lt unknown
- 2010-02-09 EP EP21152120.8A patent/EP3865128A1/en active Pending
- 2010-02-09 AU AU2010213899A patent/AU2010213899B2/en active Active
- 2010-02-09 PT PT107044646T patent/PT2395991E/pt unknown
- 2010-02-09 EP EP10704464.6A patent/EP2395991B1/en not_active Revoked
- 2010-02-09 SG SG10201400685SA patent/SG10201400685SA/en unknown
- 2010-02-09 PT PT131561227T patent/PT2596786T/pt unknown
- 2010-02-09 US US12/702,889 patent/US8293727B2/en active Active
- 2010-02-09 ES ES10704464T patent/ES2426132T3/es active Active
- 2010-02-09 SG SG10201610916SA patent/SG10201610916SA/en unknown
- 2010-02-09 RU RU2011137415/15A patent/RU2505292C2/ru active
- 2010-02-09 HU HUE16152447A patent/HUE048299T2/hu unknown
- 2010-02-09 PL PL10704464T patent/PL2395991T3/pl unknown
- 2010-02-09 KR KR1020137034936A patent/KR20140007973A/ko not_active Application Discontinuation
- 2010-02-09 PL PL13156122T patent/PL2596786T3/pl unknown
- 2010-02-09 EP EP13156122.7A patent/EP2596786B1/en not_active Revoked
-
2011
- 2011-07-29 ZA ZA2011/05612A patent/ZA201105612B/en unknown
- 2011-08-04 US US13/198,221 patent/US20110288171A1/en not_active Abandoned
- 2011-10-26 US US13/282,145 patent/US8318715B2/en active Active
- 2011-10-28 US US13/284,408 patent/US8314086B2/en active Active
-
2012
- 2012-01-12 US US13/349,153 patent/US8293728B2/en active Active
- 2012-01-12 US US13/349,150 patent/US8324195B2/en active Active
- 2012-01-12 US US13/349,157 patent/US8415335B2/en active Active
- 2012-02-23 US US13/403,694 patent/US20120156285A1/en not_active Abandoned
- 2012-02-24 US US13/404,666 patent/US20120157530A1/en not_active Abandoned
- 2012-05-29 US US13/482,720 patent/US20120237594A1/en not_active Abandoned
- 2012-06-21 HK HK12106100.0A patent/HK1165698A1/xx not_active IP Right Cessation
- 2012-09-10 US US13/608,775 patent/US8357677B1/en active Active
- 2012-09-10 US US13/608,744 patent/US8426399B2/en active Active
- 2012-09-11 US US13/610,217 patent/US8399446B2/en active Active
- 2012-09-11 US US13/610,247 patent/US8367652B2/en active Active
- 2012-09-20 US US13/623,450 patent/US8377920B2/en active Active
- 2012-12-11 US US13/711,324 patent/US8440650B1/en active Active
- 2012-12-11 US US13/711,329 patent/US8431560B1/en active Active
-
2013
- 2013-02-25 US US13/776,242 patent/US8518929B2/en active Active
- 2013-02-25 US US13/776,249 patent/US8524698B2/en active Active
- 2013-02-25 US US13/776,261 patent/US8546372B2/en active Active
- 2013-05-28 US US13/903,742 patent/US20130331447A1/en not_active Abandoned
- 2013-08-29 HR HRP20130811AT patent/HRP20130811T1/hr unknown
- 2013-09-05 SM SM201300095T patent/SMT201300095B/xx unknown
- 2013-12-10 RU RU2013154780A patent/RU2686315C2/ru active
-
2015
- 2015-02-25 PH PH12015500407A patent/PH12015500407B1/en unknown
-
2016
- 2016-12-23 HK HK16114664A patent/HK1226307A1/zh unknown
-
2017
- 2017-01-17 US US15/408,077 patent/US20170119722A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/907,707 patent/US20180185320A1/en not_active Abandoned
- 2018-07-06 US US16/029,198 patent/US20190038590A1/en not_active Abandoned
-
2020
- 2020-01-16 HR HRP20200068TT patent/HRP20200068T1/hr unknown
- 2020-01-16 HR HRP20200065TT patent/HRP20200065T1/hr unknown
- 2020-02-04 CY CY20201100099T patent/CY1122628T1/el unknown
- 2020-02-04 CY CY20201100100T patent/CY1122629T1/el unknown
- 2020-04-21 US US16/854,757 patent/US20200246300A1/en not_active Abandoned
- 2020-09-01 US US17/009,597 patent/US20210046036A1/en not_active Abandoned
- 2020-11-23 US US17/101,700 patent/US20210069142A1/en not_active Abandoned
-
2021
- 2021-01-20 US US17/153,494 patent/US20210251941A1/en not_active Abandoned
-
2023
- 2023-02-24 US US18/174,091 patent/US20240024277A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1226307A1 (zh) | 用於治療高甘油三酯血症的二十碳五烯酸乙酯 | |
PL2352497T3 (pl) | Proces przygotowania estrów aminokwasowych delta-9-thc | |
EP2550364A4 (en) | SYSTEMS AND METHOD FOR THE PRODUCTION OF EICOSAPENTAIC ACID AND DOCOSAHEXAIC ACID FROM ALGAE | |
PT2442645E (pt) | Ésteres de colina | |
EP2483233A4 (en) | HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS | |
SI2391620T1 (sl) | Z alkilaminom substituiran dicianopiridin in njegova predzdravila estra amino kisline | |
EP2444389A4 (en) | PROCESS FOR THE PREPARATION OF 2-FLUOROACRYLIC ESTERS | |
HK1194360A1 (zh) | 生產丙烯酸和丙烯酸酯的方法 | |
ZA201100528B (en) | Method for the synthesis of bioresourced acrylic acid esters | |
IL214887A0 (en) | Fatty acid monoglyceride compositions | |
EP2357164A4 (en) | PROCESS FOR THE PRODUCTION OF A -SUBSTITUTED ESTER | |
RS55972B1 (sr) | Postupci za proizvodnju akrilnih kiselina i akrilata | |
PL2734495T3 (pl) | Sposób syntezy omega-funkcjonalizowanych kwasów z kwasów tłuszczowych lub estrów tłuszczowych | |
EP2580342A4 (en) | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID USED FOR STRONG PURIFICATIONS | |
RS55954B1 (sr) | Postupci za proizvodnju akrilnih kiselina i akrilata | |
EP2542232A4 (en) | FATTY ACID INHIBITORS | |
RS56041B1 (sr) | Postupci za proizvodnju akrilnih kiselina i akrilata | |
GB0904300D0 (en) | Essential fatty acid compounds | |
ZA201107378B (en) | Process for the preparation of a biphenyl-2ylcarbamic acid ester | |
EP2488480A4 (en) | PROCESS FOR PREPARING PURE ACRYLATE SITTER | |
PT2550345E (pt) | Acendalha à base de acidos gordos | |
EP2332902A4 (en) | PROCESS FOR PRODUCING A -TRIFLUOROMETHYL-ESTER, -INSATURATED | |
PL390748A1 (pl) | Sposób otrzymywania kwasu akrylowego | |
PL390162A1 (pl) | Sposób otrzymywania kwasu akrylowego |